Chris Lehman

Mr. Lehman joined Biomarck as interim CFO advisor in April 2021. He is a seasoned financial and business development leader in the life sciences industry with an exceptional combination of strategic partnering & financial leadership experience with venture-backed private and public industry leaders in therapeutics, diagnostics, CRO and industrial biotech. Since January 2021, he has acted as lead or co-lead IPO project manager for 4 biotech companies. Earlier, as CFO of a private immune-oncology company, Mr. Lehman drove and completed all IPO readiness efforts, forming a bulge bracket underwriting syndicate, leading 3 confidential S-1 filings, and establishing SOX compliant internal control and reporting processes. He has led or supported 40+ partnering and financing transactions totaling $600+ million and has made numerous presentations to potential investors and partners in the United States, Europe, and Asia. He founded and grew a successful business development strategy consultancy with 20+ client engagements and received his MBA from the University of California at Berkeley and his BA from Yale University.